Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 17th International Conference on Malignant Lymphoma (17-ICML) was held in Lugano, Switzerland, from June 13-17, 2023, and brought together leading experts as they discussed updates in basic and translational research, clinical studies, and innovation in the field of lymphoma.
View all videos

ICML 2023

The 17th International Conference on Malignant Lymphoma
13–17 June 2023 | Lugano, Switzerland
Retweet on Twitter VJHemOnc Retweeted
jjkiladjian avatar; J.J. Kiladjian @jjkiladjian ·
10 Dec 1733663947260334511

#ASH23 a great opportunity to discuss with colleagues from #Armenia about the development of clinical research in hematology in Yerevan @NersesGH Prof. Y. Hakobyan #ArmenianHematologyAssociation

Image for the Tweet beginning: #ASH23 a great opportunity to Twitter feed image.
Reply on Twitter 1733663947260334511 Retweet on Twitter 1733663947260334511 4 Like on Twitter 1733663947260334511 18 View Tweet 1733663947260334511
Retweet on Twitter VJHemOnc Retweeted
RahulBanerjeeMD avatar; Rahul Banerjee, MD, FACP @RahulBanerjeeMD ·
10 Dec 1733660012046856430

#ASH23 HOVON analysis of dynamic frailty in #MMsm - building on work by @HiraSMian @tanyawildes et al.

Some pts get less frail with myeloma treatment đź‘Ź

Also note that, of pts who become “frailer,” some of this is artifactual because IMWG model de facto penalizes older age.

Image for the Tweet beginning: #ASH23 HOVON analysis of dynamic Twitter feed image.
Image for the Tweet beginning: #ASH23 HOVON analysis of dynamic Twitter feed image.
Reply on Twitter 1733660012046856430 Retweet on Twitter 1733660012046856430 1 Like on Twitter 1733660012046856430 6 View Tweet 1733660012046856430
VJHemOnc avatar; VJHemOnc @VJHemOnc ·
10 Dec 1733658332047856117

Great chatting with @tarekmd91 (@IcahnMountSinai) who gave an overview of updates on the use of #CART in #MultipleMyeloma

@ASH_hematology #Myeloma #MMsm #HemOnc

Image for the Tweet beginning: Great chatting with @tarekmd91 (@IcahnMountSinai) Twitter feed image.
Reply on Twitter 1733658332047856117 Retweet on Twitter 1733658332047856117 1 Like on Twitter 1733658332047856117 8 View Tweet 1733658332047856117
VJHemOnc avatar; VJHemOnc @VJHemOnc ·
10 Dec 1733649005551517749

#ASH23 | We spoke with @NersesGH from Yeolyan Hematology and Oncology Center on challenges that remain in the diagnosis and treatment of #BPDCN

@ASH_hematology #HemOnc

Image for the Tweet beginning: #ASH23 | We spoke with Twitter feed image.
Reply on Twitter 1733649005551517749 Retweet on Twitter 1733649005551517749 4 Like on Twitter 1733649005551517749 9 View Tweet 1733649005551517749
Load More...

ICML 2023

The 17th International Conference on Malignant Lymphoma
13–17 June 2023 | Lugano, Switzerland
The 17th International Conference on Malignant Lymphoma (17-ICML) was held in Lugano, Switzerland, from June 13-17, 2023, and brought together leading experts as they discussed updates in basic and translational research, clinical studies, and innovation in the field of lymphoma.
View all videos
Retweet on Twitter VJHemOnc Retweeted
jjkiladjian avatar; J.J. Kiladjian @jjkiladjian ·
10 Dec 1733663947260334511

#ASH23 a great opportunity to discuss with colleagues from #Armenia about the development of clinical research in hematology in Yerevan @NersesGH Prof. Y. Hakobyan #ArmenianHematologyAssociation

Image for the Tweet beginning: #ASH23 a great opportunity to Twitter feed image.
Reply on Twitter 1733663947260334511 Retweet on Twitter 1733663947260334511 4 Like on Twitter 1733663947260334511 18 View Tweet 1733663947260334511
Retweet on Twitter VJHemOnc Retweeted
RahulBanerjeeMD avatar; Rahul Banerjee, MD, FACP @RahulBanerjeeMD ·
10 Dec 1733660012046856430

#ASH23 HOVON analysis of dynamic frailty in #MMsm - building on work by @HiraSMian @tanyawildes et al.

Some pts get less frail with myeloma treatment đź‘Ź

Also note that, of pts who become “frailer,” some of this is artifactual because IMWG model de facto penalizes older age.

Image for the Tweet beginning: #ASH23 HOVON analysis of dynamic Twitter feed image.
Image for the Tweet beginning: #ASH23 HOVON analysis of dynamic Twitter feed image.
Reply on Twitter 1733660012046856430 Retweet on Twitter 1733660012046856430 1 Like on Twitter 1733660012046856430 6 View Tweet 1733660012046856430
VJHemOnc avatar; VJHemOnc @VJHemOnc ·
10 Dec 1733658332047856117

Great chatting with @tarekmd91 (@IcahnMountSinai) who gave an overview of updates on the use of #CART in #MultipleMyeloma

@ASH_hematology #Myeloma #MMsm #HemOnc

Image for the Tweet beginning: Great chatting with @tarekmd91 (@IcahnMountSinai) Twitter feed image.
Reply on Twitter 1733658332047856117 Retweet on Twitter 1733658332047856117 1 Like on Twitter 1733658332047856117 8 View Tweet 1733658332047856117
VJHemOnc avatar; VJHemOnc @VJHemOnc ·
10 Dec 1733649005551517749

#ASH23 | We spoke with @NersesGH from Yeolyan Hematology and Oncology Center on challenges that remain in the diagnosis and treatment of #BPDCN

@ASH_hematology #HemOnc

Image for the Tweet beginning: #ASH23 | We spoke with Twitter feed image.
Reply on Twitter 1733649005551517749 Retweet on Twitter 1733649005551517749 4 Like on Twitter 1733649005551517749 9 View Tweet 1733649005551517749
Load More...

Latest videos

View all videos
1:09
Loncastuximab tesirine: long-term survival data from LOTIS-2 & insights into the LOTIS-7 trial
Juan Alderuccio • 15 Jun 2023
1:15
SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphoma
David Bond • 16 Jun 2023
1:34
PET-guided treatment: the new standard of care in Hodgkin lymphoma?
Peter Borchmann • 15 Jun 2023
1:52
Follicular lymphoma: the value of immunotherapies & other exciting areas of research
Mitch Smith • 15 Jun 2023

DLBCL

View all
1:09
Loncastuximab tesirine: long-term survival data from LOTIS-2 & insights into the LOTIS-7 trial
Juan Alderuccio • 15 Jun 2023
0:49
SUNMO: mosunetuzumab + polatuzumab vedotin vs R-GemOx in R/R aggressive NHL
Jason Westin • 16 Jun 2023

Follicular lymphoma

View all
1:52
Follicular lymphoma: the value of immunotherapies & other exciting areas of research
Mitch Smith • 15 Jun 2023
1:30
The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials
Graham Collins • 16 Jun 2023

Immuno-oncology

View all
1:09
Loncastuximab tesirine: long-term survival data from LOTIS-2 & insights into the LOTIS-7 trial
Juan Alderuccio • 15 Jun 2023
1:15
SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphoma
David Bond • 16 Jun 2023
1:52
Follicular lymphoma: the value of immunotherapies & other exciting areas of research
Mitch Smith • 15 Jun 2023
0:49
SUNMO: mosunetuzumab + polatuzumab vedotin vs R-GemOx in R/R aggressive NHL
Jason Westin • 16 Jun 2023
The content of VJHemOnc is intended for healthcare professionals